心通口服液联合阿司匹林治疗冠心病心绞痛的临床研究

目的 探讨心通口服液联合阿司匹林治疗冠心病心绞痛的临床疗效。方法 选取2021年3月—2022年3月北京友谊医院收治的116例冠心病心绞痛患者，按随机数字表法将所有患者分为对照组和治疗组，每组各58例。对照组口服阿司匹林肠溶片，1片/次，1次/d。治疗组在对照组治疗基础上口服心通口服液，10 mL/次，3次/d。两组疗程均为4周。观察两组的临床疗效，比较两组治疗前后心绞痛发作情况、凝血功能指标D-二聚体（D-D）、纤维蛋白原（FIB）、凝血酶原时间（PT）]和炎症指标C反应蛋白（CRP）、血小板与淋巴细胞比值（PLR）、中性粒细胞与淋巴细胞比值（NLR）等]变化情况。并统计两组不良反应情况。结果 治疗后，治疗组心绞痛、心电图总有效率分别是94.83%、89.66%，均显著高于对照组的82.76%、75.86%（P＜0.05）。治疗后，两组心绞痛发作次数、硝酸甘油用量、持续时间均显著降低（P＜0.05）；治疗后，治疗组病情控制情况优于对照组（P＜0.05）。治疗后，两组血浆D-D、FIB水平均显著降低，而PT均显著延长（P＜0.05）；治疗后，治疗组凝血功能指标改善优于对照组（P＜0.05）。治疗后，两组PLR、NLR、CRP均较同组治疗前显著降低（P＜0.05）；治疗后，治疗组炎症相关指标低于对照组（P＜0.05）。治疗后，治疗组和对照组的不良反应发生率分别是8.62%、6.90%，两组比较差异无统计学意义。结论 心通口服液联合阿司匹林治疗冠心病心绞痛整体疗效显著，可显著改善机体凝血功能，抑制机体炎症状态，有效控制心绞痛发作，值得临床推广应用。

Clinical study of Xintong Oral Liquid combined with aspirin in treatment of angina pectoris of coronary heart disease

Objective To explore the clinical efficacy of Xintong Oral Liquid combined with aspirin in treatment of angina pectoris of coronary heart disease. Methods 116 Patients with angina pectoris of coronary heart disease admitted to Beijing Friendship Hospital from March 2021 to March 2022 were selected and divided into control group and treatment group according to random number table method, with 58 patients in each group. Patients in the control group were po administered with Aspirin Enteric-coated Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Xintong Oral Liquid on the basis of the control group, 10 mL/time, three times daily. The treatment course of both groups was 4 weeks. The clinical efficacy of two groups was observed. After treatment, angina pectoris attack, coagulation function index D-dimer (D-D), fibrinogen (FIB), prothrombin time (PT)] and inflammation index C-reactive protein (CRP), platelet-lymphocyte ratio (PLR), neutrophil to lymphocyte ratio (NLR)] were compared between two groups before and after treatment. The adverse reactions of the two groups were analyzed. Results After treatment, the total effective rates of angina pectoris and electrocardiogram in treatment group were 94.83% and 89.66%, respectively, which were significantly higher than 82.76% and 75.86% in control group (P < 0.05). After treatment, the frequency of angina pectoris attack, the amount of nitroglycerin and the duration of angina pectoris in both groups were significantly decreased (P < 0.05). After treatment, the condition control of treatment group was better than that of control group (P < 0.05). After treatment, plasma D-D and FIB levels were significantly decreased, but PT was significantly prolonged in both groups (P < 0.05). After treatment, the improvement of coagulation function index in treatment group was better than that in control group (P < 0.05). After treatment, PLR, NLR and CRP in 2 groups were significantly decreased compared with before treatment (P < 0.05). After treatment, the inflammation-related indexes in treatment group were lower than those in control group (P < 0.05). After treatment, the incidence of adverse reactions in the treatment group and the control group was 8.62% and 6.90%, respectively, and there was no statistical significance between the two groups. Conclusion Xintong Oral Liquid combined with aspirin has a significant overall therapeutic effect in treatment of angina pectoris of coronary heart disease, and can significantly improve the coagulation function of the body, inhibit the inflammatory state of the body, and effectively control the attack of angina pectoris, which is worthy of clinical application.